Open Access Pre-publication history

A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial

Anne Katrin Berger*, Carl von Gall, Ulrich Abel, Stefan Delorme, Matthias Kloor, Jennifer Ose, Tim Frederik Weber, Annika Stange, Georg Martin Haag, Uwe Haberkorn, Florian Lordick and Dirk Jäger

BMC Cancer 2012, 12:108  doi:10.1186/1471-2407-12-108

Pre-publication versions of this article and reviewers' reports

Original Submission - Version 1 Manuscript 23 Jan 2012
Resubmission - Version 2 Manuscript Author's comment 02 Feb 2012
Reviewer's Report Dirk Vordermark 03 Mar 2012
Editorial acceptance 08 Mar 2012
Published 22 Mar 2012